SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT07409714
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - 24 Years
- Healthy Volunteers
- Not accepted
Interventions
- Montelukast — DRUGmontelukast 10 mg daily for patients aged 15 and older, 5 mg daily for patients aged 14
- Montelukast Placebo — DRUGone microcrystalline cellulose tablet daily
Study Details
Adolescents and young adults (AYA) with type 2 diabetes (T2D) have a more severe phenotype than what is seen in youth-onset type 1 diabetes or adult-onset T2D including earlier kidney and cardiovascular disease complications; and prioritizing new treatments, either for standalone use or in combination with other therapies is critical. T2D triggers the release of proinflammatory mediators called cysteinyl leukotrienes leading to damage to the kidneys and blood vessels. This clinical trial will evaluate the effects of montelukast, a cysteinyl leukotriene inhibitor, on kidney and vascular function in AYA with T2D to help direct future diabetes care to limit diabetic kidney and cardiovascular disease complications.
Key Dates
- First listed
- Feb 13, 2026
- Start date
- Jul 31, 2026
- Status verified
- May 2026
- Primary completion
- Feb 28, 2030
- Completion
- Feb 28, 2030
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Montelukast
- Placebo Comparator: Placebo
Primary Outcome Measure
Change in renal vascular resistance (RVR) [ Time Frame: 0 and 6 months ]
Find similar trials
Related Studies
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older AdultsRecruiting · AdventHealth Translational Research Institute · Orlando, Florida
- Sleep and Glycemic Control in Type 2 Diabetes AdolescentsRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Brown Adipose Tissue Activation by Spinal Cord StimulationRecruiting · Oregon Health and Science University · Portland, Oregon
- Mechanisms of Fatigability With DiabetesRecruiting · University of Michigan · Ann Arbor, Michigan